Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning (Q34569926)

3 August 2017

Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning (English)

1 reference

3 August 2017

0 references

Kimberly C Gilmour

4

0 references

Adrian Thrasher

object named as

Adrian J Thrasher

17

0 references

author name string

H Bobby Gaspar

1

1 reference

3 August 2017

Emma Bjorkegren

2

1 reference

3 August 2017

Kate Parsley

3

1 reference

3 August 2017

Doug King

5

1 reference

3 August 2017

Joanna Sinclair

6

1 reference

3 August 2017

Fang Zhang

7

1 reference

3 August 2017

Aris Giannakopoulos

8

1 reference

3 August 2017

Stuart Adams

9

1 reference

3 August 2017

Lynette D Fairbanks

10

1 reference

3 August 2017

Jane Gaspar

11

1 reference

3 August 2017

Lesley Henderson

12

1 reference

3 August 2017

Jin Hua Xu-Bayford

13

1 reference

3 August 2017

E Graham Davies

14

1 reference

3 August 2017

Paul A Veys

15

1 reference

3 August 2017

Christine Kinnon

16

1 reference

3 August 2017

14 August 2006

1 reference

3 August 2017

1 reference

3 August 2017

14

1 reference

3 August 2017

4

1 reference

3 August 2017

505-513

1 reference

Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.06.007

PEG-ADA: an alternative to haploidentical bone marrow transplantation and an adjunct to gene therapy for adenosine deaminase deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.06.007

Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.06.007

Reduced thymic output, increased spontaneous apoptosis and oligoclonal B cells in polyethylene glycol-adenosine deaminase-treated patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.06.007

Cerebral lymphoma in an adenosine deaminase-deficient patient with severe combined immunodeficiency receiving polyethylene glycol-conjugated adenosine deaminase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.06.007

Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.06.007

Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.06.007

Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.06.007

Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.06.007

Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.06.007

Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.06.007

Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.06.007

Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.06.007

Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.06.007

High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.06.007

Failure of SCID-X1 gene therapy in older patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.06.007

Murine leukemia induced by retroviral gene marking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.06.007

Chance or necessity? Insertional mutagenesis in gene therapy and its consequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.06.007

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.06.007

Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.06.007

Potential oncogene activity of the woodchuck hepatitis post-transcriptional regulatory element (WPRE).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.06.007

Flow cytometry analysis of adenosine deaminase (ADA) expression: a simple and reliable tool for the assessment of ADA-deficient patients before and after gene therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.06.007

T-cell re-population in HIV-infected children on highly active anti-retroviral therapy (HAART)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.06.007

Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMTHE.2006.06.007

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YMTHE.2006.06.007

1 reference

3 August 2017

1 reference